CD276 and urinary bladder carcinoma: To test that, we first used CRISPR/Cas9 to delete CD276 in MB49 cells (CD276-SG), a mouse bladder carcinoma cell line, and validated CD276 KO by Western blotting (Supplementary Fig. 2l).